Advisory Board

Dr. Jivrajka is a trained cardiologist and practiced cardiology for more than 30 years. His entrepreneurial spirit has driven him to build several highly successful companies serving the health care community.

He was the founder and chairman of Episource, a health care technology company that he sold in 2023. He also founded AppleCare Medical Group, serving as president and CEO for more than 20 years before selling the business in 2010. He is currently president of Ananda Holdings, a family enterprise focused on real estate development and management.

Under Dr. Jivrajka’s leadership, AppleCare grew from 500 to 100,000 members over a span of 10 years. This robust membership was supported by a network of 400 primary care and 450 specialty physicians. A fully integrated enterprise, AppleCare used sophisticated information technology to streamline claims processing, clinical care coordination and member services. The group provided primary care throughout its service area and managed hospital care for members.

Based in Southern California, Episource supports health insurance companies and value-based medical groups across the country. The company helps manage clinical data and analytics to refine risk adjustment and quality programs. Episource developed advanced technology and operational infrastructure to collect and distribute this data across medical groups, health plans and content management systems.

In 2024, Dr. Jivrajka and his family generously established the Jivrajka Family Foundation Chair in the Division of Cardiology at the David Geffen School of Medicine at UCLA. The chair holder will focus on delivering care to patients who are disproportionately affected by heart disease, including South Asians.

Deepak Chopra is the founder of OSI Systems, Inc., a diversified global technology company that develops, manufactures and sells specialized electronic systems for security, health care, defense and aerospace, and currently serves as executive chairman of the Board of Directors. Prior to that, Mr. Chopra served as president and chief executive officer since the company's inception in May 1987 until December 31, 2024. From 1976 to 1979 and from 1980 to 1987, Mr. Chopra held various positions with ILC, a publicly-held manufacturer of lighting products, including serving as chairman of the board of directors, chief executive officer, president, and chief operating officer of its United Detector Technology division. Mr. Chopra has also held various positions with Intel Corporation, TRW Semiconductors, and RCA Semiconductors. Mr. Chopra holds a Bachelor of Science degree in electronics from Punjab Engineering College in Chandigarh, Punjab, India and a Master of Science degree in semiconductor electronics from the University of Massachusetts, Amherst.

Amita is a Los Angeles native and proud alumna of UCLA and Georgetown Law School. After leaving the practice of corporate law, Amita has focused on enriching her local communities. Amita has executed large scale events for her childrens’ schools for years, diving headfirst to lead teams of volunteers to run social and enrichment events. As a former board member of Teach AAPI (an education nonprofit focused on sharing Asian American education with schools nationwide), Amita conceptualized, organized and led a community-based cultural fundraiser for Holi as well as routinely advised on fundraising efforts for the organization.

Amita recognizes the importance of the arts and sits on the committee for the Emerging Art Fund at the Los Angeles Museum of Contemporary Art (LA MOCA) as well as the Whitney Museum’s (NY) Painting and Sculpture Committee. Amita is proud to serve on the Board of Visitors of Georgetown Law School, advising the law dean on current issues facing the law school. As part of the UCLA SAHP Advisory Board, Amita is excited to represent her alma mater in raising awareness of SAHP initiatives and health issues facing South Asian women today.

Amritraj is world-renowned for his contributions to sports as a commentator and professional tennis player. In 2022, he was recognized by the International Tennis Hall of Fame and the International Tennis Federation. He was officially inducted into the hall of fame two years later.

Amritraj has also been appointed a United Nations Messenger of Peace, given a key to the city of Los Angeles and awarded the Padma Shri, one of India’s highest civilian honors. He has acted in multiple film and TV productions as well, appearing in both the Star Trek and James Bond franchises.

Originally from Chennai, India, Amritraj has continued to work in TV, covering major tennis events. He also has experience representing businesses as a brand ambassador and traveling the world for speaking engagements. He currently lives in Southern California with his wife Shyamala and sons Prakash and Vikram.

Steven B. Fink is the former chief executive officer of Lawrence Investments, LLC, a venture with Larry Ellison of Oracle that owned and managed Mr. Ellison's non-Oracle investments. Lawrence Investments founded and invested in numerous technology, biotechnology, medical and educational companies, many of which are now public or have been acquired, including Salesforce.com, NetSuite, Quark Biosciences, Pillar Data, and Stride. Mr. Fink was founding partner, managing director, and vice chair of Knowledge Universe, a company formed to acquire, build, incubate and manage companies in the education industry. All of the companies have been either taken public or sold, but the aggregate revenues exceeded $7 billion, making the company one of the largest companies in the education industry.

Additionally, Mr. Fink was the former chair of Lexicon, one of the world's leading economic consulting companies; chair and founder Life Storage, one of the six largest owners of self-storage buildings in the U.S., sold in 2018; and was chair and CEO of Anthony's Manufacturing Company, a worldwide glass and specialty coatings company.

Further, he was a founder and chair of LeapFrog, a leading educational toy company; chair of Spring Group, a UK-based IT service company; chair of nCUBE, a massively parallel data system for distributed information; and a board member of Alteryx, a public business intelligence company; Nobel Learning, a publicly listed owner of elementary and preschools, and C-COR, a public VOIP and cable infrastructure company.

Mr. Fink is also chair of Heron International, one of the largest pan-European real estate development companies, and is the lead director of Stride, Inc, a public company with over 250,000 students in its virtual charter schools. Additionally, Mr. Fink is on the board of City of Hope, is the chair-elect of City of Hope, and chair of City of Hope's Research Enterprise/Beckman Research Institute. He was previously a board member of The American College of Physicians Foundation, the Smithsonian Institute, the UCLA Foundation, and president of Stephen S. Wise Temple.

Chief, UCLA Division of Cardiology
Chizuko and Nobuyuki Kawata Chair in Cardiology
Professor, David Geffen School of Medicine at UCLA

Dr. Hsue completed her medical degree, internal medicine residency and cardiology fellowship training at the University of California, San Franscisco. She later held a faculty position at UC San Francisco from 2002 to 2024. She also served as the Maurice Eliaser Jr. MD Distinguished Professor of Medicine and Chief of Cardiology, UC San Francisco, at Zuckerberg San Francisco General Hospital and Trauma Center.

Dr. Hsue discovered higher rates of cardiovascular disease in HIV patients and elucidated the mechanism underlying this disease progression. Her work demonstrated the role of chronic inflammation and immune activation in treated HIV — a strong predictor of future clinical events and mortality. A pioneer in HIV cardiology, her investigative efforts are multidisciplinary, innovative and paradigm-shifting.

Dr. Hsue leads clinical and translational studies on HIV-related cardiovascular disease and long COVID. Her groundbreaking research includes clinical trials of anti-inflammatory, immunomodulatory and lipid-lowering therapies — not only in the context of HIV but also in areas such as rheumatoid arthritis, atherosclerosis and most recently COVID-19.

Since 2005, Dr. Hsue has consistently received research funding from the National Institutes of Health (NIH). She has served as a principal investigator and co-investigator on numerous projects supported by NIH grants. Her extensive contributions to the field have been published in prestigious journals such as the New England Journal of Medicine, Circulation, Journal of the American College of Cardiology, JAMA Cardiology, Clinical Infectious Diseases and AIDS.

Dr. Hsue has played pivotal roles in various advisory and leadership positions. She has served as chair of both the Clinical and Integrative Cardiovascular Science Study Section and the Single-Site and Pilot Clinical Trials Study Section at the National Heart, Lung, and Blood Institute. She previously occupied a seat on the NIH Office of AIDS Research Advisory Council.

Clinical Chief, Division of Cardiology
Director, UCLA Health South Asian Heart Program – Jivrajka Initiative and UCLA Interventional Cardiology and Fellowship Training Program

Dr. Dave has been practicing medicine for more than 25 years and is board-certified in interventional cardiology and cardiovascular disease. His clinical interests include percutaneous coronary interventions using all devices, chronic total occlusions of coronary vessels, complete revascularization in high-risk patients, MitraClip mitral regurgitation procedures and percutaneous treatment for peripheral artery disease.

Dr. Dave is revered for his expertise and cultural competency when caring for patients from underrepresented ethnic groups. He is frequently sought after by South Asian patients. This community, which is at high risk of heart disease, often presents complex cases that can’t be addressed with conventional interventional procedures such as stents or bypass surgery.

Dr. Dave’s ongoing research focuses on developing applicable treatment protocols tailored to these patients — an effort that is gaining traction in the field of interventional cardiology.